Variant Bio

Variant Bio is a biotechnology company based in Seattle, founded in 2018.

The company focuses on developing life-saving therapies by studying the genes of individuals with exceptional health-related traits. It aims to enhance genomic drug discovery by leveraging human genetic diversity to understand diseases better and improve clinical trial outcomes. The company offers a range of services in genomic research, including sequencing technology, phenotyping, statistical genetics, and machine learning. Variant Bio emphasizes ethical research collaborations, particularly with underrepresented populations, ensuring that these communities benefit from the research. Its proprietary Genomic Database includes data from over 20 global populations, enhancing the understanding of genetic diversity. Variant Bio's key product is the Inference platform, an AI-driven genomic drug discovery tool that analyzes genetic data to identify new drug candidates. The company maintains a therapeutic pipeline targeting conditions such as fibrosis, kidney disease, and metabolic disorders. It collaborates with pharmaceutical and biotech partners to improve drug development success rates, while also engaging with historically underrepresented communities to ensure equitable benefits from its research initiatives.